Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as immediate release guanfacine hydrochloride, Tenex
immediate release guanfacine · 1 trial · 1 indication
QTcNi is the QT interval using a subject-specific correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
QTcNi is the QT interval using a subject-specific correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval).
QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval).
| Arm | Type | Description |
|---|---|---|
| Immediate-release Guanfacine HCl | EXPERIMENTAL | - |
| Moxifloxacin HCl | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| immediate release guanfacine hydrochloride | DRUG | Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6. |
| moxifloxacin | DRUG | Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6. |
| Placebo | DRUG | Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6. |
Inclusion Criteria: * Healthy Normal Subjects
Immediate release guanfacine is a small molecule drug developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. It is an immediate-release formulation of guanfacine hydrochloride. The drug has been studied in a Phase 1 clinical trial involving healthy volunteers, and its development is at the Phase 1 stage.
Immediate release guanfacine is made by Takeda Pharmaceutical Company Limited, which is listed on the stock exchange under the ticker TAK. Takeda is the developer of this immediate-release formulation of guanfacine hydrochloride.
Immediate release guanfacine is in Phase 1 of clinical development. One Phase 1 trial has been completed, and there are currently no active trials. The drug is investigational and has not been approved by the FDA for any indication.
Immediate release guanfacine has been studied in one completed Phase 1 clinical trial, NCT00672984, titled Guanfacine Immediate-release Electrocardiogram Results (QTc) Study. The trial enrolled 83 healthy volunteers in the United States, was randomized, double-blind, and placebo-controlled, and included participants aged 18 years and older of all sexes.
Yes, immediate release guanfacine is also known as immediate release guanfacine hydrochloride. The hydrochloride salt form is the specific chemical name for the active ingredient in this immediate-release formulation developed by Takeda Pharmaceutical Company Limited.